Alzheimer’s drug donanemab ‘not value for money’ – NICE

Getty/haydenbird

By Sarah Lowden

More evidence is needed to prove the Alzheimer’s drug donanemab is both cost and clinically effective, the NHS spending watchdog has decided.

In draft guidance, the National Institute for Health and Care Excellence said the “relatively small benefit” the treatment provides does not outweigh the cost of providing it, which requires intensive monitoring.